Sonnet Biotherapeutics Financials
| SONN Stock | USD 1.31 0.02 1.50% |
Operating Margin | Short Ratio 0.82 | EPS Estimate Current Year (27.36) | EPS Estimate Current Quarter (11.12) | Return On Equity |
Sonnet |
Sonnet Biotherapeutics Stock Summary
Sonnet Biotherapeutics competes with Day One, Mirum Pharmaceuticals, Rocket Pharmaceuticals, Avidity Biosciences, and Uniqure NV. Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey. Sonnet BioTherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US83548R1059 |
| CUSIP | 15930P404 83548R105 15930P800 83548R204 83548R303 83548R402 15930P701 15930P206 15930P305 15930P503 |
| Location | New Jersey; U.S.A |
| Business Address | 100 Overlook Center, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.sonnetbio.com |
| Phone | 609 375 2227 |
| Currency | USD - US Dollar |
Sonnet Biotherapeutics Key Financial Ratios
| Return On Equity | -2.85 | ||||
| Return On Asset | -1.34 | ||||
| Target Price | 160.0 | ||||
| Number Of Employees | 13 | ||||
| Beta | 1.01 |
Sonnet Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sonnet Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Sonnet Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sonnet Biotherapeutics competition to find correlations between indicators driving Sonnet Biotherapeutics's intrinsic value. More Info.Sonnet Biotherapeutics Holdings is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sonnet Biotherapeutics' earnings, one of the primary drivers of an investment's value.Sonnet Biotherapeutics Systematic Risk
Sonnet Biotherapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sonnet Biotherapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Sonnet Biotherapeutics correlated with the market. If Beta is less than 0 Sonnet Biotherapeutics generally moves in the opposite direction as compared to the market. If Sonnet Biotherapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sonnet Biotherapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sonnet Biotherapeutics is generally in the same direction as the market. If Beta > 1 Sonnet Biotherapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Sonnet Biotherapeutics March 28, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sonnet Biotherapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sonnet Biotherapeutics Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sonnet Biotherapeutics Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Sonnet Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sonnet Biotherapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 44.37 | |||
| Value At Risk | (6.32) | |||
| Potential Upside | 8.57 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.29) | Revenue Per Share 0.959 | Quarterly Revenue Growth 52.688 | Return On Assets (1.34) | Return On Equity |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.